Targeted treatments of bone metastases in patients with lung cancer.

Differences in survival between the ZA and placebo groups did not reach statistical significance in the normal baseline NTX subset, consistent with the lower risks of SREs and death that have been reported for that subset ( 34 , 37 ).

also in 111,027 other papers